380P - Immediate results HPV-induced cancer of the mouth and oropharynx in Kazakhstan

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Head and Neck Cancers
Presenter Galym Adilbayev
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors G. Adilbayev, G. Kydyrbayeva, V. Shipilova, Z. Sadyk, D. Adilbay
  • Head And Neck Cancer, Kazakh Reserch Institute of Oncology & Radiology, A05A2B4 - Almaty/KZ



Cancer of the oral cavity and oropharynx is an urgent global problem, and the most common form of head and neck tumors. However, in Kazakhstan, unfortunately, the study of the prevalence of HPV-associated head and neck cancer has not been conducted. We aimed to study the prevalence and the role of different types of human papillomavirus (HPV), as well as its impact on treatment outcomes and survival in patients with cancer oral cavity and oropharynx in Kazakhstan.


The study included 45 patients with morphologically verified cancer oral cavity or oropharynx I to stage IV disease. All patients before treatment received a biopsy of the tumor for PCR, IHC and ICC.


All patients with cancer of the oropharynx (21) received a competitive chemoradiotherapy according to the planned scheme. Complete tumor regression was registered in 66.6%. Partial regression of 32.5%, of which two patients from the third stage showed complete regression of primary focus and partial metastasis in the neck. Treatment without effect was seen in 1 patient. Of the 24 patients with oral cancer: of these surgery followed by radiation therapy was performed in 16 patients, and they were included in the group with full effect. Competitive chemoradiotherapy was received by 8 people. Complete tumor regression was obtained in 4 people, accounting for 50% of those who received chemoradiotherapy (8), partly - 37.5%, and treatment without effect - 12.5%. As a result of PCR study, material from 45 patients with cancer oral cavity and oropharynx in 9 revealed a positive result, one HPV type 16 genome in 6 patients, and in 3 cases a positive genome of HPV 56 type. Analysis of Ki 67 levels with IHC showed a larger proportion (60%) with moderate proliferative activity of tumors in all groups of patients studied, including 9 HPV-positive patients. Also, during the ICC proliferative activity studies showed dominance moderate tumor proliferative activity (68%), including patients with HPV-associated form.


Thus, the comparative analysis of clinical results with the PCR data, IHC and ICC noted that patients with a positive clinical effect of receiving treatment revealed moderate or low proliferative activity levels for Ki-67, including in HPV-positive patients, which could be a prognostic factor later.

Clinical trial indentification

Legal entity responsible for the study



Ministry of Education and Science


All authors have declared no conflicts of interest.